JP2015134824A5 - - Google Patents

Download PDF

Info

Publication number
JP2015134824A5
JP2015134824A5 JP2015090887A JP2015090887A JP2015134824A5 JP 2015134824 A5 JP2015134824 A5 JP 2015134824A5 JP 2015090887 A JP2015090887 A JP 2015090887A JP 2015090887 A JP2015090887 A JP 2015090887A JP 2015134824 A5 JP2015134824 A5 JP 2015134824A5
Authority
JP
Japan
Prior art keywords
compound
vitreous
cornea
pharmaceutically acceptable
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015090887A
Other languages
English (en)
Japanese (ja)
Other versions
JP6124943B2 (ja
JP2015134824A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015134824A publication Critical patent/JP2015134824A/ja
Publication of JP2015134824A5 publication Critical patent/JP2015134824A5/ja
Application granted granted Critical
Publication of JP6124943B2 publication Critical patent/JP6124943B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015090887A 2009-06-17 2015-04-27 Sap変異体及びその使用 Expired - Fee Related JP6124943B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26896109P 2009-06-17 2009-06-17
US61/268,961 2009-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012516311A Division JP5822826B2 (ja) 2009-06-17 2010-06-17 Sap変異体及びその使用

Publications (3)

Publication Number Publication Date
JP2015134824A JP2015134824A (ja) 2015-07-27
JP2015134824A5 true JP2015134824A5 (enExample) 2017-03-16
JP6124943B2 JP6124943B2 (ja) 2017-05-10

Family

ID=43354870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012516311A Active JP5822826B2 (ja) 2009-06-17 2010-06-17 Sap変異体及びその使用
JP2015090887A Expired - Fee Related JP6124943B2 (ja) 2009-06-17 2015-04-27 Sap変異体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012516311A Active JP5822826B2 (ja) 2009-06-17 2010-06-17 Sap変異体及びその使用

Country Status (10)

Country Link
US (2) US8329659B2 (enExample)
EP (2) EP2443144B1 (enExample)
JP (2) JP5822826B2 (enExample)
AU (1) AU2010262847B2 (enExample)
CA (2) CA3083911C (enExample)
DK (2) DK2443144T3 (enExample)
ES (2) ES2708823T3 (enExample)
HU (2) HUE041034T2 (enExample)
PL (1) PL2987803T3 (enExample)
WO (1) WO2010148234A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
DK2405929T3 (en) * 2009-03-11 2018-08-27 Promedior Inc SAP polypeptide for use in the treatment of autoimmune disorders and graft-versus-host disease
CA2754961C (en) * 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) * 2009-06-17 2015-11-24 プロメディオール, インコーポレイテッド Sap変異体及びその使用
EP2790690A4 (en) * 2011-12-14 2015-08-12 Texas A & M Univ Sys COMPOSITIONS AND METHODS OF MANAGING NEUTROPHILIC MOVEMENTS USING THE SERUM AMYLOID P (SAP)
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
PL3054959T3 (pl) 2013-10-08 2020-07-13 Promedior Inc. Sposoby leczenia złośliwych nowotworów zwłóknieniowych
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
JP2018512164A (ja) * 2015-04-15 2018-05-17 プロメディオール, インコーポレイテッド 骨髄増殖性障害を処置するための方法
CN108114001B (zh) * 2017-12-23 2023-05-30 中国科学院海洋研究所 一种诱导海产双壳贝类产卵的诱导剂及其应用方法
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections
MX2023005063A (es) * 2020-11-02 2023-05-12 Attralus Inc Proteinas de fusion sap fc y metodos de uso.

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023A (en) * 1847-03-20 Stocking-loom
GB1562244A (en) * 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
EP0476721B1 (en) * 1987-11-20 1995-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha A method for removing serum amyloid protein
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5272258A (en) 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
AU2158292A (en) 1991-05-31 1993-01-08 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5804446A (en) * 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US6054121A (en) * 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
WO1994027640A1 (en) 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5981470A (en) 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
ATE226829T1 (de) * 1996-01-25 2002-11-15 Profylakse Aps Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CA2321136A1 (en) 1998-02-17 1999-08-19 Medarex, Inc. Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
JP4522580B2 (ja) 1998-03-11 2010-08-11 株式会社創研 皮膚健全化剤
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6600019B2 (en) * 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1267795A1 (en) 2000-03-30 2003-01-02 Brennen Medical Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) * 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) * 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
PT1507558E (pt) * 2002-05-17 2011-11-23 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador do canal de cálcio e um diurético
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
ATE422943T1 (de) 2002-12-23 2009-03-15 William Marsh Rice Univeristy Verfahren und verbindungen zur verstärkung der fybrozyten-bildung
EP1597281A1 (en) 2003-02-27 2005-11-23 TheraVision GmbH Method for reducing levels of c-reactive protein
MXPA06011796A (es) 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
WO2006002438A2 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)
WO2006002930A2 (en) 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
AU2005282720B2 (en) 2004-09-02 2011-08-04 Genentech, Inc. Anti-FC-gamma RIIB receptor antibody and uses therefor
EP1814984A2 (en) * 2004-09-17 2007-08-08 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
PT2185581E (pt) * 2007-07-06 2015-12-09 Promedior Inc Processos e composições úteis no tratamento de mucosite
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
CA2754961C (en) * 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
DK2405929T3 (en) * 2009-03-11 2018-08-27 Promedior Inc SAP polypeptide for use in the treatment of autoimmune disorders and graft-versus-host disease
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) * 2009-06-17 2015-11-24 プロメディオール, インコーポレイテッド Sap変異体及びその使用

Similar Documents

Publication Publication Date Title
JP2015134824A5 (enExample)
JP2015509500A5 (enExample)
WO2013030679A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP7022735B2 (ja) 持続的薬物送達インプラントによる眼の状態の治療の方法
JP2017517363A5 (enExample)
WO2010105130A3 (en) Opthalmic drug delivery system and applications
JP2008538215A5 (enExample)
Mateo et al. Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation
JP2014533274A5 (enExample)
Tomey et al. Aqueous misdirection and flat chamber after posterior chamber implants with and without trabeculectomy
MX2020007948A (es) Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
JP2013513606A5 (enExample)
Park et al. Spontaneous malignant glaucoma in a longstanding hypotonous eye
MD870Y (en) Method for treating senile cataract
JPWO2022173923A5 (enExample)
Verma et al. An insight into ocular drug delivery system
Takkar et al. Re: Bouheraoua et al.: Decreased Corneal Sensation and Subbasal Nerve Density, and Thinned Corneal Epithelium as a Result of 360‐Degree Laser Retinopexy
Manayath et al. Low-fluence photodynamic therapy for early onset choroidal neovascular membrane following laser in situ keratomileusis
Hae-Won et al. Transscleral IOL Fixation With Preserved Anterior Vitreous Face in Marfan Syndrome With Ectopia Lentis
Peyman Intraocular haemorrhage: case report
Shilova et al. Novel maneuver for the alleviation of pseudophakic optic capture and consequent pupillary block: A case report and technique
Son et al. A case of malignant glaucoma in a vitrectomized eye
Nowroozzadeh Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis
Erdurmuş et al. Circumferential Pupillary Capture by IOL due to In-traocular Gas Tamponade: A Case Report
Hwang et al. The effect of posterior subtenon triamcinolone injection in panretinal photocoagulation induced visual dysfunction of diabetic retinopathy